ONVO - Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

• Organovo Holdings, Inc. is an early-stage biotechnology company developing and utilizing highly customized 3D human tissues as dynamic models of health and diseased human biology for internal drug development.
• Organovo is transitioning its short-term offering from a heavily service-based business in 2019 to drug candidate development, projecting multiple INDs by 2025.
• Organovo is in a less-than-stellar financial position with cash of $19M (Dec 2020) with a cash burn of -$15M highlighting about 1-year's worth of financing (3-Year Avg. Cash Burn: -$22M).
• Organovo changed its leadership drastically in May 2021 appointing outside financial expert Jonathan Lieber as President and CFO (no active CEO role).
• In summary, the author projects Organovo Holdings, Inc. as a long-term "risky-buy".

For further details see: